FINAL_EHA 2024 RWE Summary.pdf

RWE Studies from EHA 2024: Updates on the Treatment of CLL

EHA 2024 Summary (1).pdf

Updates from EHA 2024: Key Data on the Treatment of CLL

00_ASH2023_MtgReport_Dec_2023_01-05.pdf

Highlights from ASH 2023: Updates in the Treatment of CLL

Highlights from CCOLD 2023: Updates in the Treatment of CLL

00_ASH2022_MtgReport_Jan18_2022.pdf

Updates from ASH 2022: Updates on the treatment of CLL

01_ASH2021_Jan09_22 (1).pdf

Highlights from ASH 2021: Updates on the treatment of CLL

ASCO2021_Summary_Final.pdf

Updates from the ASCO/EHA 2021: Updates on the treatment of CLL

ASH_Report_Jan15_21.pdf

Updates from ASH 2020: Practice-changing studies in CLL

impact medicom, medical communications, medical writing

Highlights from ASCO 2020: Updates on the treatment of CLL

impact medicom, medical communications, medical writing

Updates from the ASH 2019: Practice-changing studies in treatment-naïve CLL

impact medicom, medical communications, medical writing

Updates from ASCO/EHA 2019: A Canadian perspective on high-risk cytogenetics in MM

impact medicom, medical communications, medical writing

Updates from ASH 2017: practice-changing studies in relapsed and refractory MCL

💬 416-434-8923